Investigating a new imaging agent for prostate cancer surgery
Toxicology (IND-enabling) studies for a novel nerve imaging agent for prostate cancer
This study is testing a new tool called NerveLight that helps surgeons see nerves more clearly during prostate cancer surgery, which could make the surgery safer and more effective for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Manzanita Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Woodside, United States) |
| Project ID | NIH-11006190 on NIH RePORTER |
What this research studies
This research focuses on developing NerveLight, a novel nerve imaging agent designed to enhance the safety and effectiveness of radical prostatectomies. The agent is applied topically during surgery to help visualize nerve structures, which can reduce the risk of nerve damage. The study will assess the safety and effectiveness of NerveLight through preclinical trials in animal models, specifically rats and dogs, to ensure it meets FDA guidelines for further clinical use. By using a unique Near InfraRed dye linked to nerve growth factor, the research aims to improve surgical outcomes for prostate cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adult males undergoing radical prostatectomy for prostate cancer.
Not a fit: Patients who are not undergoing prostate surgery or those with contraindications to nerve imaging agents may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer prostate cancer surgeries with reduced nerve damage and improved recovery for patients.
How similar studies have performed: Preliminary studies in animal models have shown promising results, indicating that similar approaches may be effective, although this specific application is novel.
Where this research is happening
Woodside, United States
- Manzanita Pharmaceuticals, INC. — Woodside, United States (Active)
Researchers
- Principal investigator: Kahl, Stephen B — Manzanita Pharmaceuticals, INC.
- Study coordinator: Kahl, Stephen B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.